A Phase III Trial of Eribulin Mesylate versus Capecitabine for Locally Advanced or Metastatic Breast Cancer


A Phase III Trial of Eribulin Mesylate versus Capecitabine for Locally Advanced or Metastatic Breast Cancer
Slides from a presentation at SABCS 2012 and transcribed comments from recent interviews with Kimberly L Blackwell, MD (1/8/13) and Edith A Perez, MD (1/17/13)

Kaufman PA et al. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. San Antonio Breast Cancer Symposium 2012;Abstract S6-6.

Dr Blackwell is Professor of Medicine and Director of the Breast Cancer Program at Duke Cancer Institute in Durham, North Carolina.

Dr Perez is Deputy Director at Large of the Mayo Clinic Cancer Center, Group Vice Chair of the Alliance of Clinical Trials in Oncology and Serene M and Frances C Durling Professor of Medicine at the Mayo Clinic in Jacksonville, Florida.